Retatrutide Dosage Guide: Protocols, Calculator & Safety

Goal: establish tolerance with slow uptitration — matching the Phase 2 trial schedule.

Retatrutide Phase 2 uptitration protocol — weeks 1-20

• Injection technique: subcutaneous in abdomen (2+ inches from navel), rotating sites weekly
• Timing: same day each week; time of day not critical; many users prefer evening to sleep through initial nausea
• Needle: 29-31G × 1/2" insulin syringe or supplied pen device

What to expect at each dose

• 2 mg: 4-6 weeks of mild nausea as GI adapts; modest weight loss (~2-3 kg by week 4)
• 4 mg: noticeable appetite suppression; weight loss accelerates (~4-6 kg by week 8)
• 8 mg: significant appetite suppression and satiety; weight loss substantial (~10-15 kg by week 16); nausea often resolves
• 12 mg: maximum dose; weight loss continues; side-effect burden higher; most weight loss gains occur at this dose per Phase 2 data

Required monitoring for beginners

• Baseline: HbA1c, fasting glucose, lipid panel, CMP, liver function, thyroid, resting heart rate (seated, post-rest), weight, BMI, blood pressure
• Week 4: blood pressure, heart rate, fasting glucose, subjective tolerance assessment
• Week 12: full panel + weight + body composition
• Week 20: full panel at target dose

When NOT to proceed to next titration step

• Nausea/vomiting limiting food intake or causing dehydration → hold current dose
• Heart rate increase >20 bpm from baseline → hold and cardiology consult
• Fasting glucose >130 mg/dL despite no other cause → investigate glucagon-receptor effect
• Any chest pain, severe abdominal pain, or signs of pancreatitis → stop immediately

Caveats for 2026 biohacker use

Retatrutide is NOT FDA-approved. Sourcing is typically via research-chemical vendors (with substantial quality variation) or compounding pharmacies (where available). Purity and identity verification via HPLC and mass spec is essential — more so than for established FDA-approved drugs. See our Best Peptide Vendors 2026 guide.

Goal: maintain weight loss at target dose and optimize for body composition and metabolic effect.

Retatrutide maintenance — weeks 20-52 (after successful uptitration)

• Target dose: 8-12 mg weekly SC (individualized based on tolerance and weight-loss trajectory)
• Most users settle at: 8 mg weekly — captures ~75-80% of the weight loss with ~60-70% of the side effects
• 12 mg weekly: maximum efficacy but highest side-effect burden; reserved for users with stronger weight loss goals or T2DM / NAFLD indications

Stack considerations at maintenance

• Metformin 500-1000 mg/day — synergistic with retatrutide; counters mild glycemic variability during dose changes; standard adjunct in T2DM
• Ipamorelin + CJC-1295 or Tesamorelin — lean mass preservation during the retatrutide-induced caloric deficit; the canonical body recomposition stack. Time GHS injection opposite to retatrutide peak (retatrutide has 6-day half-life so scheduling is flexible)
• MK-677 — alternative oral GHS for lean mass preservation; note: MK-677 stimulates appetite while retatrutide suppresses it — opposing signals that produce net moderated appetite
• Creatine 5 g/day — standard for lean mass preservation
• Protein 0.8-1.0 g/lb bodyweight — essential during any GLP-1-class-induced caloric deficit to preserve lean mass

Weight loss plateau management

Expect weight loss to slow after 36-48 weeks. Strategies for continued progress:

• Strength training 3-5x weekly — most effective for breaking plateau; adds lean mass that increases BMR
• Protein adjustment upward — 1.0-1.2 g/lb bodyweight in late-stage weight loss
• Dose reassessment — if at 8 mg, consider escalation to 12 mg for plateau breakthrough
• GHS stack addition or escalation — amplifies lean mass preservation
• Resistance to escalation — not all plateaus require dose escalation; some are natural adjustment to new steady state

Cycling vs continuous therapy

Retatrutide is designed as a chronic therapy — analogous to semaglutide in obesity. Cycling is not clinically indicated and typically results in rapid weight regain (6-10% weight regain in 6 months post-discontinuation, consistent with GLP-1 class data). For users pursuing cycling for non-medical reasons:

• Consider tapering down to 2 mg over 4-8 weeks rather than abrupt cessation
• Weight regain is nearly universal without continued behavior change or bridge therapy
• A bridge to lower-potency semaglutide may reduce regain but is uncommon in practice

Bloodwork on maintenance

• Every 12 weeks: HbA1c, fasting glucose, lipid panel, liver function, thyroid, blood pressure, resting heart rate, weight
• Every 6 months: Full panel + DEXA or body composition measurement
• Annually: Full panel + cardiovascular assessment + reassessment of continued indication

Goal: optimize retatrutide for specific indications beyond general weight loss — NAFLD/MASH, T2DM, cardiovascular risk reduction. For experienced users with full lab monitoring.

NAFLD / MASH protocol — 48 weeks

The Sanyal 2024 data showed 85% relative reduction in hepatic fat at 12 mg weekly for 48 weeks. For users with imaging-confirmed NAFLD (hepatic fat fraction >5%):

• Dose: 8-12 mg weekly (titrate to max tolerated)
• Duration: 48 weeks minimum; longer for persistent MASH
• Monitoring: Monthly ALT/AST, quarterly MRI-PDFF or FibroScan
• Adjuncts: Tesamorelin 2 mg/day SC adds to hepatic fat reduction via GH-driven lipid mobilization; NAD+ / NMN supports mitochondrial function under elevated fat oxidation load

T2DM optimization

• Dose: 8 mg weekly typically sufficient for HbA1c reduction equivalent to tirzepatide
• Co-therapy: Metformin 1000 mg/day is standard; sulfonylureas should be withdrawn or dose-reduced to prevent hypoglycemia
• Monitoring: HbA1c q8wk during titration, q12wk maintenance; fasting glucose weekly during uptitration
• Adjuncts: SGLT2 inhibitor (empagliflozin 10-25 mg/day) is synergistic for cardiorenal benefit and can be added after retatrutide dose stabilization

Cardiovascular risk reduction

Phase 2 data showed BP reduction ~11/5 mmHg and triglyceride reduction ~30% — meaningful cardiovascular risk modification beyond weight loss alone. For users with known CVD or high CVD risk:

• Standard 8-12 mg weekly dose
• Consider adding statin if not already; retatrutide + statin reduces LDL-C synergistically
• ACE inhibitor or ARB for any blood pressure elevation
• Regular cardiovascular assessment including possible ambulatory BP monitoring and echocardiogram at 6-12 months

Body recomposition for experienced athletes

Retatrutide + full GHS stack is the most potent recomposition configuration available:

• Retatrutide 8-12 mg weekly (caloric deficit engine)
• Tesamorelin 2 mg/day + Ipamorelin 200 mcg same injection, pre-bed (lean mass preservation + VAT reduction)
• Protein 1.0-1.2 g/lb bodyweight
• Resistance training 4-5x weekly
• Creatine 5 g/day

Expected outcomes: 20-25% body weight loss over 48 weeks, with 85-90% of loss from fat mass and VAT reduced preferentially.

Contraindications specific to advanced dosing

• Active malignancy (absolute)
• Personal or family history of MTC / MEN-2 (absolute)
• Active pancreatitis or history of pancreatitis (absolute)
• Active gallbladder disease (relative)
• Resting tachycardia (resting HR >90) — investigate cause first
• Severe heart failure (NYHA III-IV) — relative; data limited